-
-
-
-
-
-
-
Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-
-
-
-
-
-
-
Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger
-
-
-
-
-
-
-
Progenics Pharma (PGNX) Provides Update on Reconstituted Board's Ongoing Strategic Review
-
-
-
-
-
-
-
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint
-
-
-
-
-
-
-
Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer
-
-
-
-
-
-
-
Progenics Reminds Shareholders that November 17 is the True Deadline for Velan’s Consent Solicitation
-
-
-
-
-
-
-
Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors
-
1,161,584 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

